On these premises, we aimed to conduct a retrospective study based on our prospectively maintained neoadjuvant cohort to analyze the clinical significance of HER2-low status as well as to further clarify the disparities among HER2-zero, HER2-low, and HER2-positive breast cancers in patients undergoing neoadjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.